Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec Ltd
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
An open-label, multicenter extension study to evaluate the safety and tolerability of natalizumab in subjects with multiple sclerosis who have completed studies C-1801, C-1802, or C-1803
To determine the safety and the immunogenicity of extended treatment with natalizumab when administered at a dose of 300 mg intravenously (IV) to subjects with multiple sclerosis (MS) who have complet...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are Also Receiving Treatment with Levodopa
The primary objective of the study is to assess the preliminary safety and tolerability of single and multiple oral doses of BIIB014 when administered as adjunct therapy in subjects with moderate to l...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP)
To explore whether mefloquine can delay or stop progression of PML as measured by JCV levels in CSF.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
An Open-Label Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA203
To determine the safety and durability of efficacy response of long-term treatment with BG9924 when administered with a stable dose of methotrexate (MTX) to subjects with rheumatoid arthritis (RA) who...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional DMARD Therapy
To evaluate the efficacy of 5 dose regimens of BG9924 when administered in combination with MTX to subjects with active RA who have had an inadequate response to conventional DMARD therapy. The prima...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase 2B, Blinded Extension Study to Evaluate the Safety and Efficacy of BG9924 When Given in Combination With Methotrexate to Subjects with Rheumatoid Arthritis Who Previously Participated in Study 104RA202
To determine the safety and durability of efficacy response of long-term treatment with BG9924 when administered with a stable dose of Methotrexate (MTX) to subjects with rheumatoid arthritis (RA) who...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapy
The primary objective of the study is to evaluate the efficacy of BG9924 when administered in combination with MTX to subjects with active RA who have had an inadequate response to anti-TNF therapy. ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of DAC HYP compared to IFN β-1a in preventing MS relapse in subjects with relapsing remitting MS (RRMS).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
An Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects with Multiple Sclerosis who have completed Treatment in the study 205MS201 (SELECT)
To assess the safety and immunogenicity of extended treatment with DAC HYP. This evaluation will include the following major components: • An assessment of safety and immunogenicity of extended trea...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Combination with Lumiliximab Versus FCR Alone in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
The primary objective of the study is to evaluate the safety and tolerability of FCR+L compared with FCR alone in subjects with previously untreated CLL.
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
Next